Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov 28;17(11):728-732.
doi: 10.11909/j.issn.1671-5411.2020.11.005.

ARNI and SGLT2i: a promising association to be used with caution

Andrea Herbst  1 , Francesco Orso  1 , Marta Migliorini  1 , Simona Virciglio  1 , Silvia Tognelli  1 , Viola Camartini  1 , Alessandra Pratesi  2 , Francesco Fattirolli  2   3 , Niccolò Marchionni  3 , Andrea Ungar  1   2 , Samuele Baldasseroni  1
Affiliations

ARNI and SGLT2i: a promising association to be used with caution

Andrea Herbst et al. J Geriatr Cardiol. .
No abstract available

Keywords: Chronic heart failure; SGLT2i; Sacubitril/valsartan.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Sites of action of disease modify in treatments and diuretic therapy at level of nephron.
See this image and copyright information in PMC

References

    1. Ponikowski P, Voors AA, Anker SD, et al. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. doi: 10.1002/ejhf.592. - DOI - PubMed
    1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810–1852. doi: 10.1161/CIR.0b013e31829e8807. - DOI - PubMed
    1. McMurray JJ, Packer M, Desai AS, et al. PARADIGM-HF Commit-tees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective com-parison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Eur J Heart Fail. 2013;15:1062–1073. doi: 10.1093/eurjhf/hft052. - DOI - PMC - PubMed
    1. Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. doi: 10.1056/NEJMoa1504720. - DOI - PubMed
    1. Neal B, Perkovic V, Matthews DR, et al. CANVAS-R. Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19:387–393. doi: 10.1111/dom.12829. - DOI - PMC - PubMed

LinkOut - more resources